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Summary.-The combined effect of the chemotherapeutic agent ICRF-159 and radia-
tion on the proliferative status of tumour/normal systems has been evaluated using
the Lewis lung tumour in BDF1 mice. We have previously shown that a25 mg/kg dose
of ICRF-159, given at 3h intervals x4 before irradiation, significantly enhanced
tumour growth retardation relative to a single dose of 100 mg/kg before irradiation.
Whilst both single and fractionated drug treatments produced a transient inhibition
of cell proliferation, comparisons of the temporal recovery from the antiproliferative
effect ofradiation in both tumour and intestinal epithelium suggested that single acute
doses of ICRF-159 fail to potentiate the radiation response of either tissue. Protracted
drug administration before irradiation, however, markedly decreases the post-
radiation proliferative recovery of the tumour, without significantly altering intes-
tinal recovery. The data suggest that both drug concentration and/or exposure time
determine the interactions seen with combined modes.
ENHANCED efficacy of radiotherapy
when combined with the drug ICRF-159
has been reported for both experimental
tumours (Hellmann & Murken, 1974;
Norpoth et al., 1974; Peters, 1975) and in
clinical trials (Bellet et al., 1973; Ryall
et al., 1974). In the preceding report
(Kovacs et al., 1979), low-dose protracted
drug pretreatment was found to be more
effective than an acute dose for potentiat-
ing tumour-directed radiotherapy.
Relatively little information exists with
respect to the cellular action of ICRF-159
on normal dividing tissues. Gralla et al.
(1974) have reported reversible marrow
and intestinal toxicity, which were both
dose- and schedule-dependent. Most prob-
ably, optimal use ofICRF-159 in combina-
tion with radiation depends on the time/
dose effects of each modality on both
tumour cells and critical host organs. This
is particularly true when the tumour-
directed radiation field includes a sub-
stantial portion of a dose-limiting normal
tissue.
The present report presenits the differen-
tial response of the Lewis lung tumour
and the underlying intestinal epithelium of
the host after combined treatment wvith
ICRF-159 and regional irradiation of the
tumour.
MATERIALS AND METHODS
Tumottr growvth.-Male BDF1 mice obtained
from Jackson Laboratories (Bar Harbor, ME)
were inoculated s.c. in the back with 106
cells of a single-cell suspension prepared from
stock Lewis lung carcinoma (LL), originally
obtained from Linda Simpson-Herren,
Southern Research Institute, Birmingham,
AL. The LL is routinely maintained by s.c.
transplantation into BDF1 males. The mice
were maintained under a 12 h lighting
schedule, and Purina Lab Chow and water
supplied ad libitum.
ICRF-159.-ICRF-159 (NSC 129943) was
supplied by Dr H. B. Wood, Drug Synthesis
and Chemistry Branch, DCT, National Cancer
Institute. The drug was finely suspended in a
sterile solution of0-500 (w/v) carboxymethyl-
cellulose-saline (CMC-saline) and the sus-ICRF-159 ENHANCED RADIATION RESPONSE. II
pension stirred for 30 min before injection.
ICRF-159 was injected i.p. so that the volume
ofeach injection was 0-01 ml/g body wt.
Radiation.-Irradiationwasperformedwith
a General Electric Maxitron 300. The physical
factors were 275kVcp, 20 mA, H.V.L.=1*8
mmCu and TSD of 31 cm. Animals were
positioned in leucite containers in such a way
that the parts of the animal anterior to the
xyphoid process, the femurs and the tail
were shielded with lead. Animals were irra-
diated to a total dose of600rad with an expo-
sure rate of 80 rad/min.
3H-Thymidine incorporation into DNA.-
At various times during and after treatment,
4 animals from each treatment group were
injected with 50 juCi of 3H-methyl-TdR
(sp. act. 0-36 Ci/mmol, Schwarz/Mann,
Orangeburg, NY). Thirty minutes later the
animals were killed and the tumours and
jejunalsegments (4cm)removed. Thejejunum
was opened and thoroughly rinsed in iced
saline to remove material in the lumen. At
the same time, tumours were dissected and
one cross-sectional sample placed in 10%
buffered formalin for histological analyses.
The remaining tumour tissue and jejunum
were then blotted on filter paper, weighed
and placed in Carnoy's fixative for 24 h to
remove unincorporated label. The weighed,
fixed tissues were rinsed in 60% ethanol,
solubilized in Soluene (Packard Inst. Corp.)
and counted in a liquid scintillation spectro-
meter. 3H-TdR incorporation (d/min/mg
wet weight) was determined for an estimate
of the proliferative activity of the tissue
(Hagemann et al., 1971; Schenken, 1976).
Tumour-cell kinetics.-For determination
of 3H-TdR labelling index (LI) and mitotic
index (MI), the fixed tumour samples were
embedded in Paraplast, sectioned at 4 ,um,
and the sections stained by the Feulgen
method. Autoradiographs were prepared with
Kodak NTB-2 emulsion and the slides
exposed at 4°C for 14 days. Slides were de-
veloped with Kodak D-19, fixed and the LI
and MI determined microscopically from
randomly selected fields (4000 cells/tumour).
RESULTS
Effect ofICRF-159 and regional abdominal
radiation onjejunal proliferative activity
During fractionated (25 mg/kg 3-hourly
x 4) as well as acute (100 mg/kg) treat-
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FiG. 1. Proliferative response of the jejunal
epithelium to acute and fractionated
ICRF-159. (0 0), 100 mg/kg ICRF-
159 at t=O; ( *), 25 mg/kg 3-
hourly x 4from -12h.Eachpointrepresents
the mean d/min/mg± s.e. for 4 animals.
mentwith ICRF-159, proliferative activity
(d/min/mg) in the jejunum was depressed,
with a rapid return to control levels before
24 h after treatment (Fig. 1). The pro-
liferative nadirs are similar in magnitude.
Whilst fractionated drug treatment ex-
tended (z_ 30 h) the depression of pro-
liferative activity compared to acute drug
treatment (- 18 h), the recovery to con-
trol levels of proliferation was accom-
plished in 21 h from the last druge xpo-
sure for each treatment. This recovery to
control levels was followed by an over-
shoot (-.150% control), reaching a maxi-
mum at 36 h for fractionated and 48 h for
acute treatments.
The response of the jejunum to 600 rad
abdominal X-irradiation and ICRF-159-
radiation cormbinations is presented in
Fig. 2. After 600 rad alone, a rapid depres-
sion in proliferative activity occurred.
3H-TdR incorporation returned to control
levels 36-48 h after irradiation, with a
maximum overshoot of incorporation at
48 h. Neither an acute dose of 100 mg/kg
ICRF-159 (Fig. 2a) 5 min before irradia-
tion, or a fractionated pretreatment with
ICRF-159 at a dose of 25 mg/kg 3-hourly
x 4 (Fig. 2b) before irradiation altered
the initial jejunal response to 600 rad.
Retardation of the overshoot peak (48 vs
72 h) was found for both drug+radiation
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FIG. 2 (a).-The effect of combined acute
ICRF-159 and 600 rad on the proliferative
activity of the jejunal epithelium.
(A A), 100 mg/kg ICRF-159 at t=
0; (- *),600 rad at t=0; (0 O),
100 mg/kg (ICRF-159) (- 5 min) +600 rad
(t=0). Each point represents the mean
d/min/mg ±s.e. for 4 animals.
FIG. 2 (b).-The effect of combined frac-
tionated ICRF-159 and 600 rad on the
proliferative activity of the jejunal epi-
thelium. (0 O), 25 mg/kg 3-hourly
x 4 ICRF-159 from -12 h; (* 0), 600
rad at t=0; (- *), 25 mg/kg 3-hourly
x 4ICRF-l59from -12h + 600radatt--0.
Each point represents the mean d/min/mg
±s.e. for 4 animals.
treatments. But more importantly, there
was an enhanced proliferative overshoot
after fractionated drug+radiation.
Effect of ICRF-159 and X-irradiation on
the proliferative activity of LL
Unlike the jejunal response to acute
and fractionated ICRF-159, the LL
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FIG. 3 (a).-Proliferation response of the LL
tumour to acute and fractionated ICRF-
159. (0 O), 100 mg/kg ICRF-159 at
t=0; (@--*), 25 mg/kg, 3-hourly x4
from- 12 h. Eachpointrepresentsthe mean
d/min/mg is.e. for 4 tumours. Dotted lines
represent the s.e. around the mean d/min/
mg for 4 untreated tumours measured
throughout the course of the experiment.
FIG. 3 (b).-The effect of combined acute or
fractionated ICRF-159 and radiation on
the proliferative activity of the LL tumour
(- - - ), 600 rad at t=0; (0 O), 100
mg/kg ICRF-159 (t= -5min) +600rad(t=
0); ( 0) 25 mg/kg 3-hourly x4
ICRF-159 from -12 h +600 rad at t=0.
Each point represents the mean d/min/mg
±s.e. for 4 tumours.
tumour response was markedly different
for the two treatment schedules. During
the 12 h of fractionated (25 mg/kg 3-
hourly x 4) ICRF-159 treatment, the
3H-TdR incorporation gradually fell to
16% of control. Nine hours after the last
drug treatment (Fig. 3a; 6 h), the 3H-
TdR incorporation was 163% of control,
returning to control levels by 24 h after
treatment. Thereafter, the 3H-TdR levels
fluctuated around the control level for
120 h. However, after an acute dose (100
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mg/kg) of ICRF-159, the proliferative
activity appeared relatively unchanged
during the first 48 h after treatment and
exceeded control levels at 96 h (Fig. 3a).
After 600 rad X-irradiation, 3H-TdR in-
corporation fell rapidly to 45% of control
levels and fluctuated about the control
value for 120 h (Fig. 3b). There was no
evidence of compensatory proliferation
following this modest radiation exposure.
In fact, fractionated ICRF-159 was more
effective in reducing TdR incorporation
than 600 rad alone (16% vs 45%). Whilst
the initial recovery from either acute
drug (Fig. 3a) or irradiation (Fig. 3b)
occurred at the same time, the initial
recovery from fractionated drug took
place 6 h earlier.
Both acute (100 mg/kg) andfractionated
(25 mg/kg 3-hourly x 4) ICRF-159 altered
the tumour response to 600 R. Combined
acutely administered drug+radiation in-
creased the depression of 3H-TdR incor-
poration over either drug (Fig. 3a) or
radiation (Fig. 3b) alone. In addition,
initiation of post-radiation proliferative
recovery wasdelayedby 6 hafter combined
acutely administered drug+ 600 rad. Once
recovery from the combined treatment
had been initiated, it proceeded rapidly
to control levels. Following combined
fractionated drug+600 rad, proliferative
activity remained at less than 330 of
control value for 36 h and failed to return
to control levels until 84 h after treatment.
This prolonged depression of DNA syn-
thesis (cell production) was in distinct
contrast to what was observed either after
radiation alone or after the acutely ad-
ministered ICRF-159-radiation combina-
tion.
Cytokinetic response of LL to fractionated
ICRF-159+600 rad
During the fractionated pretreatment
with ICRF-159, there were changes in the
cytokinetics of the LL tumour. A 10-fold
increase in mitotic index (MI, Fig. 4b)
accompanied the 12 h drug treatment,
with a concomitant decrease in the LI
(Fig. 4a), suggesting an M-phase block in
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FIG. 4. Cytokinetic response of the LL
tumour to combinedICRF-159and 600rad.
(a) % labelled interphase cells; (b) mitotic
index. (0 O), 25 mg/kg 3-hourly
x 4ICRF-159 from - 12 h; (A A), 600
rad at t=0; (@--@), 25 mg/kg 3-hourly
x4 from --12 h +600 rad at t=0; (-)
control (mean±s.e.) for 30 tumours over a
period of168h. Everyotherpointrepresents
the mean s.e. of 4 tumours.
the cell cycle. Nine hours after the last
injection of drug (at -3 h) the LI rose
to 150% of control, while the MI fell,
suggesting a release from the M-phase
block. Control values for both LI and MI
were established at 12 h and remained
unperturbed over the next 156 h of obser-
vation. Afterirradiationwith 600radalone,
the LI gradually fell to a nadir (38% of
control) at 24 h, rose sharply by 48 h
(133% of control), and subsequently
returned to control levels by 96 h. The
wave of 3H-TdR incorporation (d/min/
mg, Fig. 3b) with no increase in LI (LI,
Fig. 4a) suggests an accelerated S-phase
transit time.
When fractionated ICRF-159 was com-
bined with 600 rad (t_ 0), arapidfallinMI
to control levels by 6 h and the marked
increase at 12 h differed conspicuously
from the response to either drug or radia-
tion alone (Fig. 4). In addition, the com-
527C. J. KOVACS, M. J. EVANS, D. R. BURHOLT AND L. L. SCHENKEN
bined treatment further depressed the
drug-induced reduction of the LI. This
reduced LI after fractionated drug+
radiation persisted for 72 h and was more
severe than with other treatments; and
initiation of LI recovery was delayed.
Recovery from both drug and radiation
alone treatment produced an LI higher
than control levels. During the recovery
from combined fractionated ICRF-159+
600 rad, the LI failed to exceed control
levels.
DISCUSSION
ICRF-159 has been reported to be both
an antiproliferative and a cytotoxic agent,
whose effects are dependent on both dose
and drug schedule (Hellmann & Field,
1970; Sharpe et al., 1970). These reports
were based on results from studies in vitro
and the cytotoxic and antiproliferative
actions ofthe drug were found to be closely
related and proliferation-dependent (Tay-
lor & Bleehen, 1977a). When ICRF-159
is used with radiation in combined
mode schedules, the drug-radiation inter-
actions are extended to the critical self-
renewing tissues such as the haemato-
poietic and intestinal epithelium, which
suffer both drug and radiation insult.
Fractionated (25 mg/kg 3-hourly x 4)
treatment with ICRF-159 before radiation
was found to retard tumour growth sig-
nificantly compared to a single dose (100
mg/kg) of the drug given 5 min before
radiation (Kovacs et al., 1978). Neither
acute nor fractionated doses of ICRF-159
alone showed intestinal toxicity. In terms
of cytokinetic effects, both treatments
produced transient intestinal insults, with
essentially similar recovery, the exception
being that fractionated drug treatment
extended the periods of antiproliferative
activity. Neither pretreatment schedule,
when combined with radiation, influenced
the immediate recovery kinetics to 600 rad
(Fig. 2). However, the maximum com-
pensatory hyperplasia was delayed by 24 h
for acute drug pretreatment, which may be
the result of either the prolonged anti-
proliferative effect of the drug or an in-
crease in crypt cellular damage (Lesher &
Lesher, 1970; Hagemann et al., 1971).
Whilst other cytotoxic agents are known
to modify the intestinal responses to
irradiation by enhanced cell kill (Hage-
mann & Concannon, 1973; Schenken et al.,
1978; Moore & Hendry, 1978), in these
studies ICRF-159, given as an acute dose
before irradiation, did not enhance animal
lethality or alter the proliferative response
of crypt cells to X-rays. However, a frac-
tionated drug effect appears to enhance
compensatory hyperplasia. This may be
attributable to antiproliferative events
associated with the drug alone. Prolonged
suppression of cell production without
attendant cell kill mayresult in subsequent
heightened proliferation.
Single acute doses of up to 1000 mg/kg,
as well as daily doses of 25 mg/kg over
a 21 day period, were tolerated by BDF1
mice, and did not produce animal lethality
or significant weight loss. Fractionated
(25 mg/kg 3-hourly x 4) ICRF-159 was
also well tolerated; however, when a dose
of5 mg/kg was delivered q 4h x 6-9, animal
mortality approached 100% within 6 days
after treatment had begun (Schenken,
unpublished).
The differences between acute and frac-
tionated ICRF-159 on proliferation are
more obvious in the LL tumour than in
the intestinal epithelium. Both fractiona-
ted and acute doses of ICRF-159 reduce
the proliferative activity of the intestinal
mucosa to nearly the same level (Fig. 1),
whereas fractionated ICRF-159 treatment
is far more effective in depressing tumour
proliferation than an equivalent acute
dose of the drug (Fig. 3a). Dose/time dif-
ferentiated effects for both the cytotoxic
and cytostatic actions of ICRF-159 on the
EMT6 cell line in vitro have been reported
(Taylor & Bleehen, 1977a). Creighton &
Birne (1970), using mouse embryo cultures
incubated with ICRF-159 for 22 h, found
a rapid inhibition of3H-TdR incorporation
into DNA increasing with concentration
up to 2 ,ug/ml. Thereafter, much greater
increases in drug concentration were re-
quired to produce additional inhibition of
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DNA synthesis. Fromtheresults presented
here (Figs. 3a and 3b) the time courses
of responses to radiation or acute treat-
ment with ICRF-159 are similar, but very
different from fractionateddrugtreatment.
During the protracted treatment with
ICRF-159, proliferative activity in LL is
depressed (Fig. 3b), primarily owing to an
accumulation of cells in mitosis (Fig. 4b)
with a concomitant decrease in the S-
phase compartment size (Fig. 4a). This is
in distinct contrast to an earlier suggestion
that ICRF-159 blocked the transit of cells
from G2 into mitosis (Sharpe et al., 1970).
Hallowes et al. (1974) have observed
that the effect of exposure to the drug is
reversible, provided a threshold-level con-
centration is not maintained in the
medium. With repeated exposures, the
drug effect was cumulative, resulting in an
inhibition of cell division with continued
DNA synthesis. Field et al. (1971) reported
a rapid, exponential clearance rate of
ICRF-159 from rat blood with a half-time
of 25 min. If the clearance rate for ICRF-
159 is similarly rapid in the mouse, treat-
ment at 3h intervals with 25 mg/kg may
not maintain a high enough concentration
of the drug for long enough to establish
an irreversible block in G2. Rather, the
transit of cells through G2 may be serially
interrupted with successive treatments,
generating increments in the mitotic
index and subsequent synchronization.
Combined treatment with ICRF-159
and radiation produces an enhanced anti-
proliferative effect in LL. Although most
radiopotentiating effects of ICRF-159
have been attributed to a drug-induced
angiometamorphic effect and its conse-
quences, rather than to an inhibition of
repair of radiation damage (Hellmann &
Murkin, 1974), Taylor & Bleehen (1977a)
have suggested that ICRF-159 substan-
tially decreases the width of the shoulder
of the radiation-response curve. However,
they suggest that ICRF-159 reduced the
ability of drug-treated cells to accumulate
sublethal damage rather than prevented
the repair of such damage (Taylor &
Bleehen, 1977b). Also, from the data
presented herein and by Peters (1975),
there is evidence ofa partial redistribution
oftumour cells into a more sensitive state.
The radiation response of a population of
cells depends to a great extent on both
the age-response function and the age-
density distribution of the population.
We have shown that fractionated ICRF-
159 treatment alters the age-density dis-
tribution of the cells within LL solid
tumours.
From these studies it seems clear that
the differences between fractionated and
acute ICRF-159 in combined-mode ap-
proaches are closely linked to the differen-
ces in the proliferative responses to the
drug. Both concentration and duration
are determinants which have been con-
sidered for the effective use of drugs in
combined-model therapy (i.e., drug-radia-
tion, drug-drug) to prevent toxicities. The
results described here suggest that low-
dose, fractionated treatment with ICRF-
159 for 12 h enhances the radiation res-
ponse ofthe tumour, but does not enhance
intestinal toxicity. We are presently in-
vestigating other ICRF-159 fractionation
schedules in a number of combined-mode
sequences.
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